Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 4/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425828 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL6730565 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3145889 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL13317630 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL8600119 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL14356311 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL7143032 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL3954465 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| SCHEMBL5981862 | 1.00 | SLC6A2 (0.44) | SLC6A2CA1CA2CA9TYR | |
| Water SCHEMBL28110031 | 0.98 | SLC6A2 (0.43) | SLC6A2CA1CA2CA9TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015197872-A1 | DERIVATIVES OF OSW-1 AND USE THEREOF FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-12-30 | — | — | WO | disclosed |
| EP-1682504-B1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-1906162-B | Hydroxypiperidine derivatives for the treatment of Gaucher's disease | AMICUS THERAPEUTICS INC | 2012-05-23 | — | — | CN | disclosed |
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7741340-B2 | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7537909-B2 | Enzymatic method of producing 4-O-β-D-galactopyranosyl-D-xylose, 4-O-β-D-galactopyranosyl-D-xylose obtained using said method, compositions contain same and the use thereof in evaluating intestinal lactase | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2009-05-26 | — | — | US | disclosed |
| EP-1682504-A4 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-1906162-A | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS INC (US) | 2007-01-31 | — | — | CN | disclosed |
| EP-1682504-A2 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | Amicus Therapeutics Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1408118-B1 | ENZYMATIC METHOD OF PRODUCING 4-0-B-D GALACTOPYRANOSYL-D-XYLOSE, 4-0-B-D-GALACTOPYRANOSYL-D-XYLOSE OBTAINED USING SAID METHOD, COMPOSITIONS CONTAINING SAME AND THE USE THEREOF IN EVALUATING INTESTINAL LACTASE | CONSEJO SUPERIOR INVESTIGACION (ES) | 2006-03-29 | — | — | EP | disclosed |
| EP-0819764-A1 | USE OF O-BETA-D-GALACTOPYRANOSYL-D-XYLOSES FOR THE PREPARATION OF COMPOSITIONS AND SOLUTIONS INTENDED TO THE EVALUATION OF INTESTINAL LACTASE, AND PRODUCTION PROCESS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 1998-01-21 | — | — | EP | disclosed |
| US-5663377-A | PROVIDING A GLYCOSIDE WHEREIN ALL THE HYDROXY GROUPS ARE PROTECTED, ARYLATING, NITRATING, REDUCING, RETINOYLATING AND DEPROTECTING GLYCOSIDE | THE OHIO STATE RESEARCH FOUNDATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5599953-A | BROMINATION OF GLUCOSE PENTAACETATE BY HYDROBROMIC ACID, PLACING AZIDE GROUP ON PROTECTED GLYCOSIDE BY REACTING WITH SODIUM AZIDE, REDUCING AZIDE TO AMINE, RETINOYLATING AND DEPROTECTING | THE OHIO STATE RESEARCH FOUNDATION (US) | 1997-02-04 | — | — | US | disclosed |
| US-5574177-A | BREAST CANCER | THE OHIO STATE RESEARCH FOUNDATION (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0732921-A1 | C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE | THE OHIO STATE RESEARCH FOUNDATION (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5516792-A | ANTICARCINOGENIC AGENTS | OHIO STATE RESEARCH FOUNDATION (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1996013258-A1 | C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE | THE OHIO STATE RESEARCH FOUNDATION (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0671953-A4 | C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE. | UNIV OHIO STATE RES FOUND (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0671953-A1 | C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011030-A1 | C-GLYCOSIDE ANALOGUES OF N-(4-HYDROXYPHENYL)RETINAMIDE-O-GLUCURONIDE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | GBA1, GAA, GBA2 | SLC6A2 3373/4885CA1 4231/4885CA2 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.